Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANGO 
AngioDynamics Inc (ANGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: ANGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.5
1 Year Target Price $18.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.87% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 550.84M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 3 | Beta 0.49 | 52 Weeks Range 6.92 - 13.63 | Updated Date 12/2/2025 |
52 Weeks Range 6.92 - 13.63 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.67% | Operating Margin (TTM) -10.43% |
Management Effectiveness
Return on Assets (TTM) -5.2% | Return on Equity (TTM) -17.1% |
Valuation
Trailing PE - | Forward PE 96.15 | Enterprise Value 494601976 | Price to Sales(TTM) 1.83 |
Enterprise Value 494601976 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 1.64 | Enterprise Value to EBITDA 276.93 | Shares Outstanding 41199844 | Shares Floating 33481877 |
Shares Outstanding 41199844 | Shares Floating 33481877 | ||
Percent Insiders 6.44 | Percent Institutions 96.37 |
Upturn AI SWOT
AngioDynamics Inc
Company Overview
History and Background
AngioDynamics, Inc. was founded in 1988. It is a provider of medical devices used by interventional radiologists, vascular surgeons, and other specialists for the minimally invasive treatment of peripheral vascular disease and other non-vascular diseases.
Core Business Areas
- Vascular Intervention & Therapies: This segment focuses on devices used in the treatment of peripheral vascular disease, including thrombus management, venous products, and drainage products.
- Oncology: This segment includes products used in the treatment of cancer, such as radiofrequency ablation (RFA) and microwave ablation (MMA) systems, as well as NanoKnife ablation systems.
Leadership and Structure
Jim Clemmer is the current President and CEO. The company has a standard organizational structure with departments focused on sales, marketing, research & development, operations, and finance.
Top Products and Market Share
Key Offerings
- AngioVac Cannula: A device used to remove thrombus or emboli from the vasculature. Market share data is not readily available; major competitors include Boston Scientific (BSX) and Edwards Lifesciences (EW).
- NanoKnife Ablation System: A system used for irreversible electroporation (IRE) ablation of soft tissue tumors. Market share data is not readily available. Competitors include Medtronic (MDT) and Johnson & Johnson (JNJ) (Ethicon).
- Radiofrequency Ablation (RFA) Probes: Devices used to ablate tumors using radiofrequency energy. Market share data is not readily available. Competitors include Medtronic (MDT) and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated, with trends including minimally invasive procedures, technological advancements, and an aging population driving demand.
Positioning
AngioDynamics occupies a niche position focusing on vascular intervention and oncology. Its competitive advantage lies in its specialized products and established relationships with key medical professionals.
Total Addressable Market (TAM)
The global medical device market is estimated at several hundred billion USD. AngioDynamics' TAM is smaller, focused on vascular and oncology applications, likely in the billions of USD range. AngioDynamics is positioned to capture a portion of this TAM through product innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Established relationships with key medical professionals
- Innovation in niche markets
Weaknesses
- Smaller market capitalization compared to major competitors
- Dependence on specific product lines
- Limited global presence compared to competitors
Opportunities
- Expansion into new geographic markets
- Development of new products and technologies
- Strategic acquisitions
Threats
- Intense competition from larger medical device companies
- Regulatory changes
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BSX
- MDT
- JNJ
Competitive Landscape
AngioDynamics faces significant competition from larger, more established medical device companies. To compete effectively, AngioDynamics must focus on innovation, niche markets, and strategic partnerships.
Major Acquisitions
BioSentry, Inc.
- Year: 2021
- Acquisition Price (USD millions): 75
- Strategic Rationale: To expand AngioDynamics' portfolio of BioSentryu00ae Biologic Implantable Sealant which is for use during open surgical and percutaneous procedures, offering immediate and sustained sealing to prevent fluid leakage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require analysis of AngioDynamics' past financial performance. Factors to consider include revenue growth, product innovation, and market expansion.
Future Projections: Future growth projections are available from analyst estimates. Consult financial data providers for specific estimates of future revenue and earnings growth.
Recent Initiatives: Recent strategic initiatives include product launches, acquisitions, and partnerships. These initiatives are aimed at driving future growth.
Summary
AngioDynamics is a medical device company focusing on niche markets within vascular intervention and oncology. While it has a specialized product portfolio and established relationships, it faces strong competition from larger players. The company's growth depends on continued innovation, strategic acquisitions, and expansion into new markets. AngioDynamics does not currently offer dividends and past acquisitions include BioSentry, Inc for $75M to expand AngioDynamicu2019s portfolio. The company also has potential to expand and capture a portion of the multi-billion TAM.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Analyst Reports, Press Releases, Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may vary. Financial data should be verified through official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AngioDynamics Inc
Exchange NASDAQ | Headquaters Latham, NY, United States | ||
IPO Launch date 2004-05-27 | CEO, President & Director Mr. James C. Clemmer | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 675 | Website https://www.angiodynamics.com |
Full time employees 675 | Website https://www.angiodynamics.com | ||
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.